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Abstract 33 
 34 
       Renal segmental metabolism is reflected by the complex distribution of the main energy 35 
pathways along the nephron, with fatty acid oxidation preferentially used in the cortex area. 36 
Ischemia/reperfusion injury (IRI) is due to the restriction of renal blood flow, rapidly leading 37 
to a metabolic switch towards anaerobic conditions. Subsequent unbalance between energy 38 
demand and oxygen/nutrient delivery compromises kidney cell functions, resulting to a 39 
complex inflammatory cascade including the production of reactive oxygen species (ROS). 40 
Renal IRI especially involves lipid accumulation. Lipid peroxidation is one of the major 41 
events of ROS-associated tissue injury. Here, we briefly review the current knowledge of 42 
renal cell lipid metabolism in normal and ischemic conditions. Next, we focus on renal lipid-43 
associated injury, with emphasis on its mechanisms and consequences during the course of 44 
IRI. Finally, we discuss preclinical observations aiming at preventing and/or attenuating lipid-45 
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Ischemia/reperfusion (I/R) injury (IRI) is the leading cause of acute kidney injury 50 
(AKI). The accumulation of lipids in renal parenchyma, also known as lipotoxicity (48), is 51 
one of the multifactorial processes occurring in IRI (63). We briefly summarize renal lipid 52 
metabolism in normal and ischemic conditions in order to help identify novel strategies to 53 
prevent lipotoxicity. 54 
 55 
Renal lipid metabolism in normal and ischemic conditions 56 
The metabolic pathways are heterogeneously compartmented along the nephron (19). 57 
Fatty acid oxidation (FAO) is the preferential source of kidney fuel (4, 29) and is active in all 58 
parts of the nephron (19, 4). Fatty acids (FA) are provided to renal cells from (51) (i) 59 
extracellular uptake, especially via FA transport proteins (such as CD36/Fatty Acid 60 
Translocase (29) or Fatty Acid Transporter Protein 1,2 or 4 (22)); (ii) in situ cytosolic 61 
synthesis (27); or (iii) release from intracellular processes, including triglyceride 62 
(TG)/phospholipid (PL) hydrolysis. The relative contribution is not fully established (47). 63 
Renal epithelial cells are also exposed to FA attached to albumin, with exacerbated toxicity in 64 
proteinuric kidney diseases (4, 15). FA can be converted to fatty acyl-CoA (FA-CoA) which 65 
enter the inner mitochondria matrix via the carnitine palmitoyl transferase (CPT) system (51). 66 
There, FA-CoA is catabolized by cyclic FAO. In addition, peroxisomes metabolize very-long-67 
chain FA in proximal tubule (PT) cells, as suggested by PT-restricted expression of the rate-68 
limiting peroxisomal enzyme, acyl-CoA oxydase (ACOX) (55). FA can also be stored as TG 69 
(Figure 1).  70 
IRI results from a transient interruption of renal blood flow, leading to a switch from 71 
aerobic to anaerobic metabolism (57). Ischemia rapidly induces the inhibition of FAO-72 
associated enzymes in both mitochondria and peroxisomes (46), as well as the reduction of 73 
CPT-1 activity (25). Changes in kidney metabolomic profiles during IRI emphasize the 74 
alteration of metabolic pathways affecting glycolysis, tricaboxylic acid (TCA) cycle and lipid 75 
metabolism (28, 56). Reperfusion is characterized by a sudden increase in oxygen 76 
concentration, which results in an increased production of reactive oxygen species (ROS) – 77 
albeit in species-associated variability (57, 62). I/R-generated ROS have (i) cell-specific and 78 
(ii) concentration-dependent impact within the renal tissue, probably related to the differential 79 
redox status between tubular and interstitial cells (31). Lipid peroxidation is a destructive 80 
process, either directly by damaging membrane structure or indirectly by releasing toxic 81 
reactive products, such as lipid aldehydes (6).  82 
 83 
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Mechanisms of lipid-associated injury 84 
Lipotoxicity refers to “accumulation of excessive lipids in non-adipose tissues, leading 85 
to cell dysfunction or death (48)”. This process has been reported in several forms of AKI, 86 
especially in IRI (14, 37, 53, 63, 68). The relative contribution of lipotoxicity to the 87 
multifactorial pathogenesis of IRI remains unknown (58). Accumulation of cholesterol (63, 88 
67) and TG (63, 68) has been documented. TG are reported as nontoxic per se but are 89 
reservoir of free FA (4, 20, 58). Furthermore, diacylglycerol (DG) and ceramide result from 90 
failed esterification or breakdown of TG (58). Thus, cell overload by free FA and downstream 91 
metabolites represent the main determinants of lipotoxicity (20, 58) .  92 
Lipid accumulation in renal IRI is not fully understood (Figures 1 and 2). On the one 93 
hand, a decrease in mitochondrial and peroxisomal FAO has been described during ischemia 94 
(46) and reperfusion (21) periods. On the other hand, an increase of PL hydrolysis (56), FA 95 
uptake (27, 68, 70) and lipid synthesis (27, 70) has been suggested. These cascades cause a 96 
mismatch between FA availability versus utilization. TG accumulation may not only result 97 
from alterations in TG and FA synthesis, but also from FA uptake and TG catabolism (27). 98 
PL degradation during IRI arises from various processes (57), such as enhanced cytosolic, 99 
mitochondrial and microsomal phospholipase A2 (PLA2) enzymatic activities (41) and [Ca
2+
] 100 
alteration (60). However, total plasma membrane (PM) PL biomass appears well preserved ex 101 
vivo after PT hypoxia (69). 102 
Lipid accumulation in kidneys is either protective or toxic depending on the time 103 
course of IRI and, therefore, the duration and extent of lipid overload (63). Initially, 104 
cholesterol and TG accumulation may be considered as protective in stabilizing PM and 105 
buffering free FA (34, 64, 66, 68). In an murine model of renal IRI, ischemia acutely results 106 
in a 3- to 4-fold increment in renal cortex [cholesterol ester], which lasted for up to 2h post 107 
reperfusion and which is mostly due to an increased flux of free cholesterol to the 108 
endoplasmic reticulum (67). However, profound and sustained adenosine triphosphate (ATP) 109 
depletion hampers the esterification of free FA to TG (57). TG progressively accumulate in 110 
the renal cortex after ischemia. TG levels are already significantly increased at 1 day post 111 
ischemia, with a peak at 1 week and a 3-week plateau (63). Such an ongoing accumulation of 112 
lipids may partially contribute to the evolution from AKI to CKD after IRI (29, 51, 63). 113 
Additionally, metabolomics have reported elevated levels of glycerol at early IRI time-points, 114 
suggesting TG lipolysis as a source of free FA (56). Hence, when cell capacity for TG storage 115 
is overpassed or in case of TG hydrolysis (48), lipid-induced cell dysfunction or death could 116 
theoretically occur through multiple pathways (48): (i) protein acylation, (ii) opening of the 117 
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mitochondrial permeability transition pore (3, 11, 43) and altered mitochondrial energy 118 
coupling (11, 43); (iii) membrane damage (37), (iv) release of proinflammatory/ proapoptotic 119 
factors and activation of apoptotic pathways; (v) ferroptosis (1, 33, 39); and (vi) increased 120 
cellular oxidative (23, 26, 49) and reticulum endoplasmic (RE) stresses (30). Particularly, the 121 
cell death process called ferroptosis is associated with lipid peroxidation and is characterized 122 
by the loss of activity of glutathione peroxidase 4 (Gpx4), a key enzyme in the repair of PM 123 
(13). The functional loss of Gpx4 results in an iron-dependent lethal accumulation of lipid 124 
hydro-peroxides (1). Lipid metabolism is closely related to cell sensitivity to ferroptosis since 125 
the accumulation of polyunsaturated FA influences the extent of lipid peroxidation and, in 126 
turn, ferroptosis (54). In addition, high levels of free FA may result in their auto-oxidation to 127 
lipid peroxides, secondary to the overwhelming of RE metabolism capacity (46). The level of 128 
lipid peroxides has been reported 250% higher in ischemic versus control kidneys in a rat 129 
model of IRI (46). Moreover, FA accumulation is observed in persistently impaired ATP 130 
production by mitochondria (3, 10, 12, 59). Non-esterified fatty acids (NEFA) may function 131 
as protonophoric uncouplers of oxidative phosphorylation, as well as openers of the 132 
mitochondrial permeability transition pore (10, 61). A decrease in mitochondrial membrane 133 
potential and an abrogation of mitochondrial proton gradient are both involved in NEFA-134 
induced protonophoric mitochondrial uncoupling (9, 10, 12). Finally, PLA2 also plays a key 135 
role in ATP recovery following renal IRI. In an in vitro model using PT segments exposed to 136 
hypoxia/reoxygenation, exposure to exogenous PLA2 lowered ATP concentration and 137 
ATP/ADP ratio by 40 and 70%, respectively. This effect was most likely due to the release of 138 
arachidonic acid from cell membranes (65).  139 
 140 
Strategies to prevent lipid-associated injury in renal ischemia/reperfusion 141 
The general approaches for the prevention or treatment of lipotoxicity include 142 
measures that (i) decrease the global lipid content in target tissues by increasing lipid 143 
catabolism and/or lipid excretion; (ii) transfer lipids towards adipose tissue; and (iii) target 144 
critical pathways of FA-induced cell death (48) (Figure 2). 145 
Agonists of peroxisome proliferator-activated receptor α (PPARα) have been widely 146 
investigated in renal IRI. PPARα are ligand-activated transcription factors that belong to the 147 
nuclear hormone receptor superfamily, of which target genes are involved in lipid metabolism 148 
(18). In renal IRI, PPAR expression decreases (52). In preclinical studies, PPARα agonists, 149 
like fibrates, are nephroprotective (8, 32, 44, 52). They help maintain FAO with FA as major 150 
source of energy production, as well as prevent lipid accumulation and peroxidation (36). In 151 
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rats, administration of PPARα activators 5 days prior to renal I/R improved renal function, in 152 
association with an increased mRNA and protein levels of ACOX and cytochrome P4A1 (45). 153 
In a model of renal IRI in KAP2-PPARα transgenic mice, testosterone-induced up-regulation 154 
of PPARα protected kidney function and morphology, notably via reduced formation of lipid 155 
peroxidation products (32). Recently, polyacetylene glycoside has been reported to increase 156 
both CPT-1 and PPARα expression in hypoxic tubular epithelial cells and mouse ischemic 157 
kidneys, thereby leading to FAO enhancement and reduced lipotoxicity (70). Nevertheless, 158 
the putative nephroprotection of fibrate-induced PPARα modulation in the clinical settings of 159 
renal IRI remains unproven.  160 
Another promising candidate concerns propinoyl-L-carnitine (7, 16, 24), a short-chain 161 
acyl derivative of L-carnitine, which may (i) help restore tissue carnitine, the essential 162 
cofactor for free FA uptake into mitochondrial matrix, and (ii) replenish mitochondrial TCA 163 
intermediates (38). In an ex vivo rat model of IRI, ischemic preconditioning with propionyl-L-164 
carnitine attenuated renal damage. Moreover, this compounds prevented delayed graft 165 
function in a syngeneic rat model of kidney transplantation (38). Interestingly, in addition to 166 
attenuated oxidative stress and improved energy metabolism, pretreatment with L-carnitine 167 
significantly decreased the hydrolysate products of PL, including lysophosphatidylcholine and 168 
free FA. These observations suggest a decreased activity of PLA2 (35). Similarly, the 169 
upregulation of CPT-1 activity by C75 compound alleviated renal IRI in rats (25). 170 
Other pharmacological interventions aiming at reducing the generation or effects of 171 
ROS may block signaling pathways contributing to lipid-associated injury (40). These may 172 
include (i) antioxidant enzymes, such as superoxide dismutase and catalase, (ii) ROS 173 
scavengers, such as tempol (5), (iii) agents preventing ROS production, such as 174 
desferrioxamine (17), and (iv) agents inhibiting ROS-generating enzymes, such as  175 
allopurinol against xanthine oxidase (5). Despite extensive preclinical research in the field of 176 
lipid peroxidation, most of the potential benefits have not yet been translated into clinical 177 
practice. 178 
Anti-ferroptosis compounds may also represent a pharmacological strategy for 179 
ischemic conditioning (13). In a necroptosis-insenstitive murine model, the inhibition of 180 
ferroptosis by the ferrostatin derivative 16-86 resulted in reduced levels of acyl-CoA 181 
synthetase long-chain family member 4, a key enzyme of FA metabolism. Still, no benefit 182 
was observed in IRI severity (39). Conversely, Linkermann et al. showed that the 183 
administration of ferrostatin attenuated renal IRI in mice (33). Alpha-tocopherol and 184 
desferoxamine have also been successfully tested in a murine model of IRI (2, 42). 185 
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Finally, several compounds have been studied against renal lipotoxicity, with no focus 186 
on renal IRI (48), or in ischemic conditioning, with no focus on energy/lipid modulation. 187 
Among them, pharmacological activators of AMP-activated protein kinase (AMPK) are of 188 
particular interest in ischemic conditioning (50). AMPK is an energy sensor of which 189 
downstream targets include the phosphorylative inhibition of acetyl-CoA carboxylase (ACC). 190 
ACC is one of the central enzymes involved in FA homeostasis. ACC-induced carboxylation 191 
of acetyl-CoA leads to the production of malonyl-CoA, a substrate for FA synthesis but also a 192 
potent inhibitor of CPT-1 (24). One preclinical study reports a slight effect of AMPK-193 
associated recovery of CPT-1 activity, with no effect on malondialdehyde levels (24).  194 
   195 
Conclusion and perspectives 196 
A better understanding of renal metabolism may help determine if and how lipid 197 
modulation can be pharmacologically targeted to develop new approaches against IRI. 198 
Combined therapies are most probably required to achieve an efficient renal conditioning. 199 
Several compounds attenuating lipid-associated injury have been tested in preclinical models 200 
of renal IRI, with promising observations. Still, well-designed prospective randomized 201 
controlled clinical trials are needed to assess their translational relevance.  202 
203 
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Legends of the Figures 405 
 406 
Figure 1. Schematic overview of lipid metabolism in renal tubular cell 407 
The normal physiology is depicted in blue and detailed in text. Briefly, processes contributing 408 
to fatty acid (FA) pool include: (i) extracellular uptake, (ii) in situ cytosolic synthesis or (iii) 409 
release from intracellular processes. FA can be converted to fatty acyl-CoA (FA-CoA), which 410 
enters the inner mitochondria matrix via the carnitine palmitoyl transferase (CPT) system. 411 
There, FA-CoA is catabolized by cyclic FA oxidation (FAO). Peroxisomes metabolize very 412 
long-chain FA. FA can also be stored into TG. AMPK is an energy sensor, with downstream 413 
targets including the acetyl-CoA carboxylase (ACC). PPARα are ligand-activated 414 
transcription factors of various genes involved in lipid metabolism. 415 
(↓) or (↑) represent metabolism modulations caused by renal ischemia/reperfusion (I/R). 416 
Decreased delivery of oxygen results in the lowering of the intracellular pH (due to 417 
accumulation of lactic acid) and the [ATP] levels. I/R causes (i) a decrease of FAO with a 418 
decline in CPT- activity 1 and the inhibition of FAO-associated enzymes in both 419 
mitochondria and peroxisomes; and (ii) a downregulation of PPARα. Increased PLA2 activity 420 
and FA uptake have been reported. Under circumstances of a mild ATP reduction (*), an 421 
increased synthesis of lipids may also contribute to lipid accumulation (27). Of note, the I/R-422 
associated metabolic changes sequentially occur during I/R. 423 
ACC; acetyl-CoA carboxylase, ACOX, acyl coA oxidase; AMPK, AMP-activated protein 424 
kinase ; ATP, adenosine triphosphate; CAT, carnitine translocase ; CPT; carnitine palmitoyl 425 
transferase; DGAT, diglyceride acyltransferase; VLCFA, very long chain fatty acid; PLA2, 426 
phospholipase A2; PPAR α, peroxisome proliferator-activated receptor α. Broken lines 427 
indicate multi-step processes. 428 
 429 
Figure 2. Lipid-associated injury in renal ischemia/reperfusion, and potential 430 
pharmacological approaches 431 
Renal ischemia/reperfusion (I/R) causes a mismatch between FA availability versus 432 
utilization, leading to lipid accumulation. Lipid-induced cell dysfunction/death involve 433 
multiple pathways (48): (i) protein acylation, (ii) opening of the mitochondrial permeability 434 
transition pore (3, 11, 43) and altered mitochondrial energy coupling (11, 43); (iii) membrane 435 
damage (37), (iv) release of proinflammatory/ proapoptotic factors and activation of apoptotic 436 
pathways; (v) ferroptosis (1, 33, 39) and (vi) increased cellular oxidative (23, 26, 49) and 437 
reticulum endoplasmic (RE) stresses (30).  The panels represent strategies evaluated in 438 
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preclinical models to limit lipid-associated I/R injury. 439 
AMPK, AMP-activated protein kinase ; CPT; carnitine palmitoyl transferase; FA, fatty acid; 440 
PPAR α, peroxisome proliferator-activated receptor α. 441 
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